緑膿菌感染症治療薬の世界市場-2022-2029年

市場力学

緑膿菌による院内感染の増加

緑膿菌感染症治療薬市場の成長は、緑膿菌による院内感染の増加、抗菌薬耐性の急速な向上、緑膿菌感染症治療薬の研究開発の増加などが主な要因となっています。

尿路感染症（UTI）、肺炎、嚢胞性線維症、血流感染症など、緑膿菌に関連する院内感染の増加が、予測期間中の世界の緑膿菌感染症治療薬市場の成長を牽引すると予想されます。集中治療室における緑膿菌感染症の発生率が上昇しており、これが新しい緑膿菌感染症治療薬の需要を押し上げると予測されています。米国疾病対策予防センター（CDC）によると、米国では年間約51,000件の医療関連緑膿菌感染症が発生しています。このうち6,000件以上（13％）が多剤耐性菌であり、これらの感染症が原因で年間約400人が死亡しています。病院内感染（HAI）による死亡率の増加は、特に免疫不全の患者さんにおいて緑膿菌が原因であることが分かっています。ヘルスケア関連感染症の約35％は、呼吸器感染症、泌尿器感染症、消化器感染症、その他の疾患を引き起こし、緑膿菌治療薬の需要増につながっています。

また、緑膿菌感染症の治療における抗生物質の使用量が増加していることも、市場の成長を後押ししています。緑膿菌感染症の治療に抗生物質の使用が増加しているため、抗生物質耐性菌の出現により、この治療法はほとんど効果がありません。このような状況の中、製薬会社は耐性菌の治療法開発に注力しています。これは、緑膿菌感染症治療市場のプレーヤーが活用するための十分なホワイトスペースを提供します。

投資の増加と広範な研究開発が、新規治療法の開発を後押ししています。主要プレイヤーは、非抗生物質による治療オプションの研究開発に多額の投資を行っています。複数の製薬会社が、抗生物質と化学的類似性を持つ新規化合物の試験を行っています。研究開発のための資金調達の増加は、市場の成長を後押しすると予想されます。例えば、2021年11月、同種細胞療法の新しいアプローチの開発に投資した前臨床段階の企業であるPlateletBioは、この分野の先駆的アプローチを進めるためにシリーズB融資ラウンドで7550万米ドルを調達しました。同社は、血小板の生物学に基づく新しい同種細胞療法を開発しています。同社のリード候補は、自己免疫疾患である免疫性血小板減少症（ITP）を対象に前臨床開発中です。また、2022年7月には、臨床段階のバイオテクノロジー企業であるCarmot Therapeutics, Inc.が、代謝性疾患や癌における疾患修飾療法の発見と開発を目的とした創薬プラットフォーム「Chemotype Evolution」に1億6000万米ドルの資金を投資すると発表しています。

しかし、抗生物質の長期使用は患者への悪影響につながり、市場成長の妨げになる可能性があります。しかし、緑膿菌は薬剤耐性を示すため、資金力に乏しい創薬企業は市場から撤退しています。

目次

第1章 調査手法と調査範囲

• 調査手法
• 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

• 治療別の市場内訳
• 薬物クラス別市場内訳
• 投与経路別市場内訳
• 流通経路別市場内訳
• 地域別市場内訳

第4章 市場力学

• 市場影響因子
  • 促進要因
    • 病院内感染（HAI）の頻度上昇
    • 緑膿菌に対する創薬への投資の増加
  • 抑制要因
    • 緑膿菌の薬剤耐性能力
• ビジネスチャンス
• 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• 疫学
• パイプライン分析
• サプライチェーン分析
• 価格設定分析
• 法規制分析
• アンメットニーズ
• COVID-19影響度分析

第6章 治療法別

• 単剤治療
• 併用療法

第7章 薬物クラス別

• アミノグリコシド
• モノバクタム系
• カルバペネム
• セファロスポリン
• その他

第8章 投与経路別

• 鼻腔
• 経口
• 静脈内投与

第9章 流通経路別

• 病院内薬局
• 小売薬局
• オンライン薬局
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A（合併・買収）分析

第12章 企業プロファイル

• Teva Pharmaceutical Industries Ltd.
  • 企業概要
  • 製品ポートフォリオと説明
  • 主なハイライト
  • 財務概要
• AbbVie Inc.（Allergan plc）
• Pfizer, Inc.
• Merck & Co., Inc.
• AstraZeneca
• Bristol-Myers Squibb Co.
• Lupin Pharmaceuticals, Inc.
• Janssen Pharmaceuticals, Inc.
• Gilead Sciences Inc.
• Novartis AG（LIST NOT EXHAUSTIVE）

第13章 DataM

Market Overview

Pseudomonas aeruginosa infection treatment market was valued at USD 1.31 billion in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 6.5% during the forecast period (2022-2029).

Pseudomonas Aeruginosa (also known as P. aeruginosa) is an important cause of gram-negative infection, especially in patients with compromised host defense mechanisms. Pseudomonas aeruginosa is a multidrug-resistant pathogen known for its intrinsically advanced antibiotic resistance mechanisms, its antibiotic resistance mechanisms, and its association with serious illnesses including hospital-acquired infections (HAIs) such as ventilator-associated pneumonia and various sepsis syndromes. These bacteria frequently cause urinary tract infections (UTIs), lung infections, pneumonia, and chronic pain. People with a low immune system are highly prone to affect by this infection.

The incidence of Hospital Acquired Infections (HAIs) has increased in recent years. As P. aeruginosa infection is one of the common infections in a hospital facility, the chances of being diagnosed with P. aeruginosa infection are high. This has led to an increase in research and development to find the treatment for P. aeruginosa. Several drugs are in the pipeline phases for the treatment of this infection.

Market Dynamics: rising incidences of nosocomial infections associated with P. aeruginosa

The pseudomonas aeruginosa infection treatment market growth is majorly driven by the rising incidences of nosocomial infections associated with P. aeruginosa, rapidly growing antibacterial resistance, and increasing research & development of pseudomonas aeruginosa infection treatments.

The rise in the prevalence of nosocomial infections associated with P. aeruginosa, such as urinary tract infection (UTIs), pneumonia, cystic fibrosis, bloodstream infection, and others, are expected to drive the growth of the global pseudomonas aeruginosa infection treatment market over the forecast period. There is a rise in the incidence of pseudomonas aeruginosa infections in intensive care which is projected to boost the demand for newer pseudomonas aeruginosa infection treatment drugs. As per the Centers for Disease Control and Prevention (CDC), about 51,000 healthcare-associated pseudomonas aeruginosa infections occur in the United States annually. Over 6,000 (13%) of these are multidrug-resistant, with around 400 deaths per year attributed to these infections. The growing mortality rate owing to hospital-acquired infection(HAIs) is caused due to P. aeruginosa bacteria, especially in immunocompromised hosts. About 35 % of healthcare-acquired infections cause respiratory system infections, urinary infections, gastrointestinal infections, and other disorders, which leads to a rise in the demand for pseudomonas aeruginosa treatment.

In addition, increasing the usage of antibiotics for the treatment of pseudomonas aeruginosa infection is also driving market growth. Owing to the increasing use of antibiotics for the treatment of P. aeruginosa infection, the emergence of antibiotic-resistant bacterial strains has this line of treatment almost ineffective. In this scenario, pharma companies are focused on developing a treatment approach for the same. This provides ample white space for players in the pseudomonas aeruginosa infection treatment market to capitalize on.

The rising investments and extensive research & development are boosting the development of novel therapies. The major players are investing heavily in R&D for non-antibiotic treatment options. Several pharma companies are testing novel compounds that bear chemical similarities with antibiotics. Increasing funding for research and development is expected to boost market growth. For instance, in November 2021, PlateletBio, a preclinical stage company that invested in developing a new approach to allogeneic cell therapies, raised $75.5 million in a Series B financing round to advance its pioneering approach to the field. The company is developing new allogeneic cell therapies based on platelet biology. Its lead candidate is in preclinical development for immune thrombocytopenia (ITP), an autoimmune disease. Also, in July 2022, Carmot Therapeutics, Inc., a clinical-stage biotechnology company announced to invest 160 million USD financing for drug discovery platform, Chemotype Evolution, to discover and develop disease-modifying therapies in metabolic disease and cancer.

However, extended use of antibiotics leads to harmful effects on the patient, which is likely to hamper the market growth. However, as P. aeruginosa shows the ability of drug resistance, several drug developers, who have limited funds are dissuaded from the market.

Market Segmentation: therapy segment for the highest share in global pseudomonas aeruginosa infection treatment market

The pseudomonas aeruginosa infection treatment market is classified by medication into monotherapy and combination therapy. Among these, the combination therapy segment accounted for the largest market share in the global pseudomonas aeruginosa infection treatment market in 2021. Combination therapy is used for the patient who has developed resistance property against monotherapy. During this therapy, a combination of different drugs is used to treat bacterial infections. The rise in drug resistance in monotherapy has increased the demand for combination therapy for the treatment of pseudomonas aeruginosa infection. As per the research, combination therapy showed promising results and the mortality was lower in patients receiving combination therapy, compared to monotherapy. Also, the growth of combination therapy for the treatment of P. aeruginosa infection is due to its rapid onset of action, high bioavailability rate, cost-saving, and high efficiency. Hence, these factors are expected to boost the growth of the combination therapy segment.

Based on drug class, the global pseudomonas aeruginosa infection treatment market is segmented into cephalosporin, aminoglycoside, carbapenem, monobactam, and others Among these, the cephalosporin segment held the largest market share in 2019, owing to the increasing development of a new class of cephalosporin for the treatment of various P. aeruginosa infections by significant companies. A new cephalosporin (fifth-generation) was developed for the treatment of gram-negative bacteria such as P. aeruginosa, methicillin-resistant staphylococcus aureus, and others. The launch of a new cephalosporin class of drugs is likely to boost the growth of the segment.

Based on the route of administration, the global pseudomonas aeruginosa infection treatment market has been segmented into oral, nasal, and intravenous. The intravenous segment is expected to dominate the global pseudomonas aeruginosa infection treatment market during the forecast period because most of the drugs available for the intravenous route as it gives rapid onset of action and high accuracy in dosing compared with other routes. Most physicians prefer the intravenous route for the administration of drugs, as in the intravenous route, the entire dose reaches the systemic circulation immediately with rapid onset of action against bacteria.

Geographical Penetration: North America is the dominating region during the forecast period.

North America region is dominating the global pseudomonas aeruginosa infection treatment market accounted for the largest market share in 2021, owing to rising incidences of nosocomial infections associated with P. aeruginosa, such as urinary tract infection (UTIs), pneumonia, cystic fibrosis, bloodstream infection, and others. As per the the Centers for Disease Control (CDC) estimates that HAIs account for an estimated 1.7 million infections and 99,000 associated deaths each year. In addition, 32 percent of all healthcare-acquired infection are urinary tract infections and 22 percent are surgical site infections. According to the Provincial Infection Control Network of British Columbia, HAIs are a major patient safety issue and economic burden for the healthcare system. In Canada, one in every nine hospital patients contracts a healthcare-associated infection. It is estimated that each year in Canada, there are more than 220,000 cases of HAI in Canada hospitals, resulting in at least 8,000 deaths. As Pseudomonas aeruginosa infection is common, the probability of this infection is still prevalent in these countries. The U.S. and Canada have a well-developed health care system that encourages research and development for the treatment of these infections. These countries have a major presence of diverse global market players. As high and increasing demand is met by the presence of global players in the region, the market is further expected to increase.

Europe is the second-largest market for pseudomonas aeruginosa infection treatment in terms of market value, due to rising incidences of pseudomonas aeruginosa infection, the presence of major players, and the early adoption of new products. For instance, in Germany, about 22,000 to 33,000 people are suffering from pseudomonas aeruginosa infection.

The Asia-Pacific pseudomonas aeruginosa infection treatment market is expected to grow at the fastest growth rate over the forecast period. Developing countries such as China, India, and South Korea are expected to be lucrative markets over the forecast period, owing to growing awareness, increasing incidences of healthcare-associated pseudomonas aeruginosa infection, rapidly developing healthcare infrastructure, and high demand for advanced therapeutics. About 165,000 to 180,000 people in Australia suffer from hospital-acquired infections, as per a study, and of these, about 9,000 have pseudomonas aeruginosa infection.

Competitive Landscape:

The global players are manufacturing the majority of the pseudomonas aeruginosa infection treatment drugs and therapies. Some of the key players which are contributing to the growth of the market include AbbVie Inc. (Allergan plc), Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Co., Lupin Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Gilead Sciences Inc., Novartis AG, among others.

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the pseudomonas aeruginosa infection treatment market globally. For instance

In April 2021, CARB-X funded up to 5.3 million USD to Phico therapeutics to develop an engineered bacteriophage drug to treat ventilator-associated pneumonia caused by drug-resistant pseudomonas aeruginosa.

In May 2021, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., launched generic erythromycin tablets in the USA. Teva generic Erythromycin tablets are indicated to treat a variety of bacterial infections and to prevent initial or recurrent attacks of rheumatic fever in patients allergic to penicillin. The tables are available in sizes of 250 mg and 500 mg.

In September 2019, Armata Pharmaceuticals, a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, has developed a new synthetic phage candidate targeting the pathogen Pseudomonas aeruginosa to treat serious respiratory infections, with an emphasis on cystic fibrosis patients.

In March 2019, Allergan received the U.S. FDA approval for the AVYCAZ treatment of complicated intra-abdominal infections (cIAI) and urinary tract infections (cUTI) in pediatric patients.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

• 3.1. Market Snippet by Treatment
• 3.2. Market snippet by Drug Class
• 3.3. Market snippet by Route of Administration
• 3.4. Market Snippet by Distribution Channel
• 3.5. Market Snippet by Region

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Prevalence of Hospital Acquired Infections (HAIs)
    • 4.1.1.2. Growing Investment in Drug Discovery for Pseudomonas Aeruginosa
    • 4.1.1.3. XX
  • 4.1.2. Restraints:
    • 4.1.2.1. Drug Resistance Ability of Pseudomonas Aeruginosa
    • 4.1.2.2. XX
• 4.2. Opportunity
• 4.3. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Epidemiology
• 5.3. Pipeline Analysis
• 5.4. Supply Chain Analysis
• 5.5. Pricing Analysis
• 5.6. Regulatory Analysis
• 5.7. Unmet Needs
• 5.8. COVID-19 Impact Analysis

6. By Treatment

• 6.1. Introduction
• 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Segment
• 6.3. Market Attractiveness Index, By Treatment Segment
  • 6.3.1. Monotherapy*
    • 6.3.1.1. Introduction
    • 6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 6.3.2. Combination Therapy

7. By Drug Class

• 7.1. Introduction
• 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
• 7.3. Market Attractiveness Index, By Drug Class Segment
  • 7.3.1. Aminoglycoside*
    • 7.3.1.1. Introduction
    • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 7.3.2. Monobactam
  • 7.3.3. Carbapenem
  • 7.3.4. Cephalosporin
  • 7.3.5. Others

8. By Route of Administration

• 8.1. Introduction
• 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
• 8.3. Market Attractiveness Index, By Route of Administration Segment
  • 8.3.1. Nasal*
    • 8.3.1.1. Introduction
    • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 8.3.2. Oral
  • 8.3.3. Intravenous

9. By Distribution Channel

• 9.1. Introduction
• 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
• 9.3. Market Attractiveness Index, By Distribution Channel Segment
  • 9.3.1. Hospital Pharmacies*
    • 9.3.1.1. Introduction
    • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 9.3.2. Retail Pharmacies
  • 9.3.3. Online Pharmacies
  • 9.3.4. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. U.K.
    • 10.3.7.3. France
    • 10.3.7.4. Italy
    • 10.3.7.5. Spain
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. Australia
    • 10.5.7.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Teva Pharmaceutical Industries Ltd.*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. AbbVie Inc. (Allergan plc)
• 12.3. Pfizer, Inc.
• 12.4. Merck & Co., Inc.
• 12.5. AstraZeneca
• 12.6. Bristol-Myers Squibb Co.
• 12.7. Lupin Pharmaceuticals, Inc.
• 12.8. Janssen Pharmaceuticals, Inc.
• 12.9. Gilead Sciences Inc.
• 12.10. Novartis AG (LIST NOT EXHAUSTIVE)

13. DataM Intelligence

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us